Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;60(6):693-699.
doi: 10.1002/mus.26689. Epub 2019 Sep 10.

Factors associated with acute exacerbations of myasthenia gravis

Rohit Reddy Gummi  1 , Natalie Anna Kukulka  1 , Chelsea B Deroche  2 , Raghav Govindarajan  3
Affiliations

Factors associated with acute exacerbations of myasthenia gravis

Rohit Reddy Gummi et al. Muscle Nerve. 2019 Dec.

Abstract

Introduction: The etiology of acute exacerbations of myasthenia gravis (MG) is not well understood and further characterization can lead to improved preventative measures. This study aims to characterize factors contributing to MG exacerbations.

Methods: A total of 127 MG patient charts were reviewed retrospectively (2011-2016) to obtain demographics, immunizations, pharmaceutical records, contributing factors of each MG exacerbation, emergency department (ED) visits, hospitalizations, and duration.

Results: There were 212 exacerbations requiring 106 ED visits and 141 hospitalizations (average admission 6.5 days). Highest contributors were infections (30%) and medications that may worsen MG (19%), with 24% unattributed. Infection related exacerbations were associated with 44.3% of ED visits and 39.7% of hospitalizations. Patients prescribed beta-blockers were associated with more exacerbations (P < .01). Patients prescribed medications that may worsen MG had a higher exacerbation frequency shortly after administration.

Discussion: Infections and cautioned medications are frequently factors in acute MG exacerbations needing urgent medical attention and warrant caution.

Keywords: exacerbation; infection; medication; myasthenia gravis; vaccine.

PubMed Disclaimer

References

REFERENCES

    1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8:475-490.
    1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023-1036.
    1. Phillips LH. The epidemiology of myasthenia gravis. Ann N Y Acad Sci. 2003;998:407-412.
    1. Kaminski HJ, Daroff RB. Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol. 2000;57:752-753.
    1. Peppa M, Krania M, Raptis SA. Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review. Integr Blood Press Control. 2011;4:7-16.

Publication types

MeSH terms

LinkOut - more resources